This proposal considers the following working model to explain how polyclonal T cell stimulation can promote human SLE. 1) Naturally- occurring environmental agents can trigger in vivo polyclonal T cell activation in all hosts. 2) Such polyclonal T cell activation normally results in polyclonal activation of both helper T cells and downregulatory T cells. 3) The polyclonally activated helper T cells have the capacity to promote activation and differentiation of many (if not all) B cells, including those capable of producing pathogenic autoantibodies. 4) The polyclonally activated downregulatory T cells counterbalance this autoimmunity-promoting response, at least in part, via physical lysis of cells crucial to polyclonal Ig production (including the B cells themselves). 5) The numerically small CD8+56+ T cell subset is the predominant effector of this polyclonal downnregulatory CTL activity. 6) Polyclonal downregulatory CTL activity mediated by CD8+56+ T cells is impaired in SLE, allowing for enhanced survival of the cells crucial to polyclonal Ig production and enhanced opportunity for the relevant B cell to produce pathogenic autoantibodies. 7) The CTL defect is a predisposing factor in SLE pathogenesis. This proposal will focus on 4 specific questions based on this working model. 1) Do normal CD8+56+ T cells potently downregulate polyclonal Ig production, and is such CD8+56+ T cell-mediated downregulation impaired in SLE? 2) How are normal downregulatory CD8+56+ T cells generated, and what are the defects in SLE? 3) How do normal CD8+56+ T cells effect their downregulation, and what is the defect in SLE? 4) Does the SLE defect in CD8+56+ T cells antedate onset of overt clinical disease? The answers to these questions should shed considerable light on fundamental pathogenetic immune disturbances in human SLE.
Showing the most recent 10 out of 25 publications
